Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166445 | 0.71 | — | — | |
| SCHEMBL4180707 | 0.69 | — | — | |
| SCHEMBL29992917 | 0.67 | GAA (0.42) | GAAMAPT | |
| SCHEMBL16245754 | 0.67 | GAA (0.42) | GAAMAPT | |
| SCHEMBL10692876 | 0.65 | — | — | |
| SCHEMBL1919337 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL17593296 | 0.64 | — | — | |
| SCHEMBL3886432 | 0.62 | — | — | |
| SCHEMBL6306595 | 0.62 | GAA (0.40) | GAAMAPT | |
| SCHEMBL7215350 | 0.62 | GAA (0.36) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109338-B2 | For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1380575-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6541470-B1 | Have a potent antiviral activity against picornaviruses and rotaviruses. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MAVS, IRF3, EIF2AK2 | GAA 943/4885MAPT 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.